"TREATMENTS" · 총 69건
필터 보기현재 지수
49.5
0 = 부정 우세
50 = 중립
100 = 긍정 우세
최근 7일 기준 81,265건을 분석한 결과, 뉴스 심리지수는 49.5(균형)입니다. 긍정 10,118건(12.5%)·중립 58,569건(72.1%)·부정 12,578건(15.5%)이며, 중립 비중이 뚜렷하게 높습니다. 성향 지수는 종합 20.6(보수 경향)입니다.
A specialized psychiatric treatment program helped this 24-year-old with her complex OCD. Now, her family owes the facility more than $1 million.
It's never been easier to love your smile.
One of the world's leading cancer specialists has spoken to FRANCE 24 about how people need more support to modify their habits to help prevent cancer. Professor Antoine Italiano is just back in France after attending the world's largest cancer conference in Chicago. He told us about new detections and treatments, as well as his own speciality of antibody drugs. He spoke to us in Perspective.
The measure would also shield providers from extradition to states that have banned such treatments.
Infertility treatment procedures in South Korea rose nearly 40 percent over four years, according to data from the Health Insurance Review and Assessment Service. A total of 203,101 procedures, including discontinued cycles, were performed in 2023, up 38.9 percent from 146,354 in 2019. By procedure type, artificial insemination fell 12.2 percent to 31,591 cases over the cited period, while in vitro fertilization jumped 55.4 percent to 171,510 cases. Single-cause infertility accounted for 67.5 pe
Health secretary Robert F. Kennedy Jr.’s new autism panel is championing a controversial communication method popular among parents of severely autistic people. Critics warn of abuse — and fake “telepathy.”
The government will market its new “small trader scheme” as an effort to bring retailers into the tax net and generate Rs50 billion annually. A cursory look would, however, reveal that it is less a tax reform initiative and more a negotiated settlement with one of Pakistan’s most under-taxed yet politically influential constituencies. The scheme offers traders with annual sales of up to Rs200 million a simplified one per cent turnover tax on a voluntary basis. Participants will face minimal compliance requirements and will be exempt from audits, point-of-sale systems, digital invoicing and most forms of scrutiny. Existing non-filers can join under certain conditions. The government insists this is not a tax amnesty. But exempting traders from the very documentation tools — POS [point-of-sale] systems, digital invoicing — that the state claims to be expanding elsewhere makes that position hard to sustain. If the purpose is to integrate retailers into the documented economy, the scheme does the opposite. It risks entrenching the cash-based practices that have long kept retail trade outside the tax net. This follows a familiar pattern. Whenever governments attempt to broaden the tax base, trader resistance produces a compromise — a concessionary regime that falls short of genuine documentation. The Tajir Dost Scheme, introduced last year, largely failed; at one point, only a few dozen traders had reportedly joined. The new scheme is a variation of the same scheme, not a more effective alternative. The OICCI notes that the corporate sector, representing only 6pc of GDP, accounts for nearly 60-70pc of direct tax revenues, while retailers remain under taxed The scale of what is being forgone deserves emphasis. Pakistan’s retail sector is estimated to generate annual turnover in the range of Rs10 to Rs15 trillion, yet its contribution to direct tax revenues remains negligible. The Overseas Investors Chamber of Commerce & Industry’s (OICCI) tax proposal submissions to the government note that the corporate sector, representing only 6pc of GDP, accounts for nearly 60-70pc of direct tax revenues. That concentration is not a sign of corporate wealth; it is a sign of how narrow and distorted the tax base has become. The Rs50bn target attached to this scheme, even if met, would represent a fraction of what full compliance at standard rates could theoretically yield. Every scheme that keeps retailers outside the documented economy worsens that distortion. The contrast with salaried workers and corporations is too obvious. Formal-sector employees have taxes deducted automatically at source and face progressive rates that rise sharply with income. Corporations bear some of the highest effective tax rates in the region and must meet extensive reporting requirements. The OICCI has calculated that the effective burden on large corporates, once super tax, Workers Welfare Fund and Workers Profit Participation Fund contributions are included, reaches 45-46pc. For resident shareholders, the combined burden approaches 64pc, figures that place Pakistan among the most heavily taxed corporate jurisdictions in the region. A retailer turning over hundreds of millions of rupees, meanwhile, can now settle tax liabilities through a preferential regime while avoiding audits and documentation that other taxpayers cannot escape. This is not an equitable distribution of the tax burden; it is a distortion that the scheme deepens. That this sector continues to shoulder such rates while retailers negotiate preferential arrangements is the predictable result of repeatedly choosing accommodation over enforcement. The International Monetary Fund (IMF), whose conditions explicitly include broadening the tax base and reducing reliance on withholding taxes from a narrow set of documented taxpayers, has flagged the retail and wholesale sectors as critically under-taxed. Whether this scheme satisfies or contradicts its commitments with the fund is a question the government is unlikely to answer publicly, and one the IMF is unlikely to ignore when the next review comes around. The OICCI, representing the largest foreign investors operating in Pakistan, has explicitly called for all future tax exemptions and preferential treatments to pass through a transparent policy review mechanism under the proposed Tax Policy Office. The small trader scheme announced without any such review is precisely the kind of ad hoc concession that the body was designed to prevent. That the government bypassed this process, which it has itself committed to operationalising, raises questions about whether the Tax Policy Office will have any real authority or will simply be overridden whenever political costs become inconvenient. The political logic is straightforward. Traders are an important constituency for the ruling PML-N in urban Punjab. They are well-organised and capable of mobilising quickly. Mandatory documentation, digital invoicing and strict enforcement would carry real political costs. A voluntary, audit-free arrangement does not. The political costs of confronting traders are not hypothetical. When the government attempted to impose a minimum tax of Rs3,000 per shop in FY23, the then finance minister Miftah Ismail was publicly rebuked — not by the opposition, but by PML-N leader Maryam Nawaz Sharif. The message to traders, and to any future finance minister contemplating enforcement, was unambiguous. But that calculation has consequences: every concession granted to retailers increases pressure on sectors that are already fully documented and easy to tax. Revenue collection alone is not the benchmark for sound tax policy. Effective reform must broaden the tax base, improve documentation and distribute the burden more fairly. On those standards, the Fixed Tax Asaan Scheme fails. A credible alternative roadmap is not difficult to design. The tools and the blueprint are available. The OICCI, in its taxation proposals, has outlined one: a two-year programme to bring unregistered businesses into the tax net through digitisation, integration of existing databases and expansion of digital invoicing. That this framework has been formally submitted to the government and set aside in favour of a voluntary, audit-free scheme is telling. The OICCI has warned that the continued concentration of tax burden on the formal sector has already contributed to multinational companies scaling down operations or exiting Pakistan altogether. A tax policy that drives out documented, compliant investors while offering relief to undocumented ones does not just fail on fairness grounds; it actively undermines the investment base the country needs to grow its way out of fiscal stress. Published in Dawn, The Business and Finance Weekly, June 8th, 2026
At 43, Izabel Provost became a mother of three after more than four years of fertility treatments, multiple miscarriages and significant financial and emotional challenges.
• Targets entire family of viruses, animal-borne strains; aims to thwart future pandemics; initial-phase trials of 39 participants succeeded; larger efficacy studies loom • Experts hail move as ‘pivotal leap’ for humanity • Approach could end need for regular flu vaccine updates A “FUNDAMENTALLY new” vaccine designed entirely by artificial intelligence has been tested in people for the first time, in what researchers at the University of Cambridge describe as a potential breakthrough in the effort to prevent future pandemics, BBC reported. This experimental approach seeks to establish immunity against a broad range of viruses, including all known coronaviruses, rather than targeting a single circulating strain. Traditional vaccine development typically relies on a currently circulating viral strain. However, certain viruses are adept at mutating, causing conventional vaccines to lose efficacy quickly. This is why seasonal flu and Covid shots require regular updates. “We’re always behind,” Professor Jonathan Heeney of Cambridge told the BBC, noting his team’s goal is to reverse this dynamic. “What we’re trying to do is get ahead of the curve.” The researchers claim it is the first time a vaccine’s key component has been designed entirely by AI and then trialled in people. To achieve this, researchers compiled genetic codes — the biological instruction manuals — from coronaviruses documented by global surveillance programs. An AI system analysed these sequences to design a “super-antigen.” Antigens are essential components of vaccines that train the immune system to attack foreign invaders. This super-antigen trains the immune system to defend against the entire family of viruses, providing immunity even if viruses mutate or a new infection jumps from animals to humans. The technology is “surprising all of us”, Heeney said, adding it is “amazing what we can do with it for the good of humanity”. “This is about making vaccines that protect us, not just from today’s viruses, but protect us from what can cause the next outbreak or disease,” Heeney said. “This is a fundamental shift in how we prepare for pandemics.” Initial trials involving 39 participants assessed safety. A subsequent study of approximately 200 individuals will test how effectively the vaccine stimulates the immune system. Findings published in the Journal of Infection indicated that the impact on the immune system was “modest,” yet the results continue to generate excitement. Prof Saul Faust of the University of Southampton, who led some of the trial work, said the AI-driven approach “definitely has potential” and described it as “really exciting”. “What’s really interesting is the technology is an awful lot better at designing vaccines for potential pandemics when viruses are changing,” he said. While coronavirus research remains in early stages, the team is leveraging the technology to develop vaccines for other ailments. According to the report, they are conducting animal research into a universal seasonal flu vaccine to eliminate the need for annual updates. They are also developing a vaccine for the H5N1 bird flu. Researchers are also exploring inoculations for viral hemorrhagic fevers, including Ebola species. The BBC highlighted that the ongoing outbreak in the Democratic Republic of Congo is caused by an Ebola species currently lacking a targeted vaccine. Professor Andy Pollard, director of the Oxford Vaccine Group, who was not involved in the Cambridge study, told the outlet that the methodology is producing compelling evidence. “It’s fascinating data, and people wouldn’t have predicted they’d be able to generate these immune responses,” Pollard said. Pollard cautioned that human trials will determine success, as human immune systems differ from those of laboratory mice. Broadly, Pollard characterised AI as a “game changer” for vaccine research, predicting it will accelerate development and “save lives”. Professor Marian Knight, scientific director for the National Institute for Health and Care Research, described the trial as a “pivotal leap forward in our ability to deliver broad, lasting viral protection”. “Another British science success story, this is a great example of how we can bring our research expertise together with AI to deliver new treatments,” UK’s Science Minister Lord Vallance said. “With the first human trials showing positive results, this work could help speed up the rollout of vaccines to benefit people all over the world for the long term.” Published in Dawn, June 6th, 2026
“The good physician treats the disease; the great physician treats the patient who has the disease” — Sir William Osler (1849-1919) IN 1986, Carlo Petrini founded the ‘slow food’ movement in Italy to counteract the so-called ‘fast food’, by promoting local food cultures, traditional cooking and sustainable farming. Inspired by this, the concept of ‘slow medicine’ took birth: a patient-centred approach to healthcare that prioritises time, listening, and comprehensive care over rapid, high-tech, intensive interventions. It emphasises quality, the patient’s context and shared decision-making to avoid hurried, unnecessary, harmful treatments. There is no doubt that modern medicine is revolutionising healthcare. In emergency situations diagnoses are generated in minutes. Imaging technologies are replacing exploratory surgery. Algorithms now identify patterns invisible to the human eye. This advancement has saved countless lives. Yet amid this relentless drive for efficiency, questions are emerging: what do we lose in this fast-paced medicine? Most health challenges are the result of an imbalance in our lives, and most quick-fix solutions actually exacerbate these imbalances. The slow medicine approach focuses on identifying the root cause of our health challenges, creating a thoughtful, step-by-step and long-term response to restore balance in our lives, because good care requires time, attention, and reflection. It reminds us that patients are not just a set of signs and symptoms to be fixed, but individuals whose illnesses are embedded in social, psychological and cultural contexts. For countries like Pakistan, slow medicine is particularly relevant. Slow medicine is built on three principles: careful deliberation before intervention; minimal necessary treatment rather than maximal possible treatment; and respect for the patient’s lived experience and values. It asks physicians to pause and think before acting. In medicine, as in life, acting quickly is not always acting wisely. The concept has gained attention in response to the global problem of overdiagnosis, overtreatment and rising costs of healthcare. As diagnostic tools become more sensitive, medicine increasingly detects abnormalities that may never cause harm. Small lesions, borderline results and incidental findings often mean further tests and interventions, leading to unnecessary physical, psychological and financial stress. Slow medicine offers a different approach. It suggests that not every abnormal result or every symptom requires a battery of tests and immediate action. Observation, patience, context and careful history-taking can be more valuable in many situations. Although the principles of slow medicine can be applied to any clinical interaction, there are at least four areas where they are most relevant. Chronic diseases such as diabetes, hypertension and cardiovascular disease evolve over years, shaped by lifestyle, environment and stress. Managing them effectively requires careful and thoughtful history-taking, a good doctor-patient relationship, continuity of care and gradual adjustment. Understanding why the condition exists in the first place is more important than simply making changes to the prescription. Secondly, mental health conditions such as depression, anxiety and trauma are closely related to relationships and social contexts. In healthcare systems like Pakistan, mental health consultations are brief, fragmented and heavily reliant on medications. Very few psychiatric consultations end without a prescription. Yet psychological healing often depends on something more essential: being listened to and understood — things that cannot be rushed. Geriatric care is another area. Older patients frequently have multiple conditions, medications and vulnerabilities. Aggressive interventions may prolong life but at the cost of dignity and comfort. Slow medicine shifts the question from ‘what more can we do?’ to ‘what is worth doing?’ In many cases, less intervention results in better quality of life. End-of-life care perhaps represents the most profound expression of slow medicine philosophy. The goal is no longer cure but care: relief of pain and suffering, preserving dignity, and respecting patients’ and family’s wishes. This requires patience, tolerance and time and cannot be rushed. For countries like Pakistan, slow medicine is particularly relevant. Many of the country’s health problems are shaped by societal conditions: poverty, unemployment, rampant inflation, political uncertainty, violence, etc leading to medicalisation of social distress. Patients and physicians both get trapped in seeing these problems through the biomedical lens, ie, quick assessment in which patients’ complaints are addressed through various lab and radiology tests, followed by medicines, while the root cause of their complaints are hardly ever asked about or addressed. Doctors are neither trained nor feel comfortable enquiring about social factors as most wonder that even if they inquire about them what can they can do about it. No wonder the burden of almost all conditions — communicable and non-communicable — is extremely high in Pakistan. Ultimately, slow medicine is not about rejecting urgency where it is necessary — emergencies demand rapid action, and modern medicine excels in such moments. It is about recognising that much of healthcare does not occur in emergencies. It unfolds over time — in chronic illness, in mental health, in ageing and in recovery. In these areas, haste can do more harm than good. At its heart, slow medicine is a reminder of what medicine has always aspired to be: not just a technical but a human one — one that demands not only scientific advancement, but also wisdom, humility, compassion and humanity. It asks clinicians to see beyond the scan, the lab report and the prescription pad, and to engage with the person behind the patient. It reminds us that the true practice of medicine is in caring for people. In 1953, Sir Robert Hutchison wrote A physician’s prayer: “From inability to let well alone; from too much zeal for the new and contempt for what is old; from putting knowledge before wisdom, science before art, and cleverness before common sense; from treating patients as cases; and from making the cure of the disease more grievous than the endurance of the same, Good Lord, deliver us.” More than 70 years later, his prophetic words remain strikingly relevant to modern medicine. The writer is professor emeritus, psychiatry, Aga Khan University. mmkarticle@gmail.com Published in Dawn, June 6th, 2026
A grand jury subpoenaed the health system for information about adolescent patients who had received gender-related care, Mount Sinai said on Friday.
Skip the in-spa treatments for now.
More than two dozen studies suggest the treatments are linked to lower cancer risk, reduced metastasis and improved survival, though researchers say trials are needed to confirm any anti-cancer benefit.
As scientists edge closer to new treatments for hair loss, Victoria Derbyshire examines what such breakthroughs could mean for women.
SANTIAGO, Chile (AP) — When a rare but deadly rodent-borne virus struck passengers on a cruise ship and seemed to be spreading, there were no treatments for those who fell ill and no vaccines to protect others. That was the case even though it wasn’t a novel germ that the world had never seen before, […]
The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering a patient's DNA
Cancer researchers highlighted several treatment breakthroughs during their annual summit in Chicago that concluded Tuesday, including preliminary but encouraging data on potential benefits of weight loss medications. The post Cancer researchers present advances and emerging treatments appeared first on Vanguard News.
Citing data from the State Health Agency (SHA), the government said over Rs 84 crore had been spent on the treatment of bone, joint and trauma-related illnesses
An investigation into couples who have had shocking experiences in fertility clinics. Plus: more perfect comedy with Amandaland. Here’s what to watch this evening 7pm, BBC Two Like many couples, Beth and Laura went to northern Cyprus for separate IVF treatments and chose the same sperm donor for their two children. But DNA test results later suggested the siblings weren’t blood-related. In this astonishing investigation, Anna Collinson asks: “Have loose rules and little regulation led to wrongdoing?” She speaks with the brother and sister, and learns they aren’t the only family affected. Hollie Richardson Continue reading...
A new drug in development has shown promising results in restricting cancer cells’ ability to hide from the immune system and reduced tumors in some patients by at least 30%. Immunotherapy treatments for cancer have improved survival rates, but due to cancer’s ability to play “hide-and-seek,” many drugs become ineffective. However, Greywolf Therapeutics, an Oxford-based ...